Related Experiment Video
Updated: Jun 6, 2026
04:12
Roller Microneedle Combined with Tranexamic Acid Solution in Treating Melasma
Published on: January 19, 2024
MITF-siRNA formulation is a safe and effective therapy for human melasma
Xiang Yi1, Guang Zhao, Hongjie Zhang
1Center for Systems Biology, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
Summary
Topical siRNA effectively lightens hyperpigmented skin by reducing melanin synthesis. This microphthalmia-associated transcription factor-siRNA (MITF-siR) cream offers a safe and effective treatment for melasma.
Area of Science:
- Dermatology
- Molecular Biology
- Gene Therapy
Background:
- The therapeutic potential of siRNA-based agents for various diseases remains under investigation.
- Melasma and other hyperpigmentation disorders represent significant dermatological challenges.
- Targeting key genes in melanin synthesis pathways offers a potential therapeutic strategy.
Purpose of the Study:
- To evaluate the safety and efficacy of microphthalmia-associated transcription factor-siRNA (MITF-siR) cream for treating facial hyperpigmentation.
- To assess the impact of MITF-siR on melanin synthesis and related gene expression.
- To explore the potential of siRNA-based agents for dermatological applications.
Main Methods:
- Development of a novel transdermal peptide-based cream formulation containing MITF-siR.
- Clinical evaluation of hyperpigmented facial lesions in subjects treated with MITF-siR cream over 12 weeks.
- Assessment of gene expression levels for tyrosinase (TYR), tyrosinase-related protein 1, and MC1R.
- Colorimetric and melanin content analysis of treated skin lesions and adjacent normal skin.
Main Results:
- MITF-siR significantly reduced MITF gene expression, leading to decreased levels of TYR, tyrosinase-related protein 1, and MC1R.
- Topical MITF-siR cream demonstrated significant lightening of hyperpigmented facial lesions within 4 weeks, with 90.4% improvement after 12 weeks.
- Treatment resulted in a 26% decrease in melanin content in lesions and a 7.4% decrease in adjacent normal skin.
- The siRNA formulation showed significant lightening of melasma and normal skin in Asian individuals, indicating a safe profile.
Conclusions:
- Topical MITF-siR cream is a safe and effective therapy for facial hyperpigmentation, such as melasma.
- siRNA-based agents hold promise for developing novel treatments for dermatological conditions, including melanoma.
- Targeted gene silencing via siRNA represents a viable strategy for modulating melanin production.
Related Concept Videos
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...